Literature DB >> 18375292

Percutaneous transluminal angioplasty (PTA) alone versus PTA with balloon-expandable stent placement for short-segment femoropopliteal artery disease: a metaanalysis of randomized trials.

Yajun E1, Nengshu He, Yi Wang, Hailun Fan.   

Abstract

PURPOSE: To evaluate and compare the results of percutaneous transluminal angioplasty (PTA) and stent placement to treat femoropopliteal artery occlusive disease.
MATERIALS AND METHODS: Published data of randomized clinical trials comparing the results of PTA and stent placement for femoropopliteal artery occlusive disease were analyzed. Proportions were combined, and the odds ratio (OR) with its 95% CI was used as the effect size estimate.
RESULTS: Seven studies published in 1999 or later (614 limbs in 519 patients) were included in this metaanalysis, in which 323 limbs underwent PTA and 291 limbs underwent PTA followed by balloon-expandable stent placement. In the combined results of PTA versus PTA plus stent placement, a significant difference in primary patency at 6 months (OR, 0.47; 95% CI, 0.27-0.84; P < .05) was found, but no significant difference could be found in primary patency at 12 months (OR, 1.27; 95% CI, 0.87-1.86; P > .05) or 24 months (OR, 1.22; 95% CI, 0.81-1.82; P > .05) or in secondary patency at 12 months (OR, 1.34; 95% CI, 0.78-2.30; P > .05).
CONCLUSIONS: In the treatment of femoropopliteal artery occlusive disease (< or =10 cm), higher primary patency rates can be expected at 6 months with PTA followed by implantation of balloon-expandable stents versus PTA alone, but PTA with stent placement does not produce better long-term primary results and secondary patency rates than PTA alone.

Entities:  

Mesh:

Year:  2008        PMID: 18375292     DOI: 10.1016/j.jvir.2007.12.446

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  11 in total

Review 1.  Peripheral arterial disease.

Authors:  Kevin Cassar
Journal:  BMJ Clin Evid       Date:  2007-07-01

Review 2.  Peripheral arterial disease.

Authors:  Kevin Cassar
Journal:  BMJ Clin Evid       Date:  2011-01-11

3.  Prognostic significance of osteopontin in acute myeloid leukemia: A meta-analysis.

Authors:  Yong-Bing Chen; Si-Mei Ren; Si-Dan Li; Zhongli Du
Journal:  Mol Clin Oncol       Date:  2017-06-28

4.  Stenting for peripheral artery disease of the lower extremities: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2010-09-01

5.  Prognostic and clinicopathological significance of glypican-3 overexpression in hepatocellular carcinoma: a meta-analysis.

Authors:  Jia Li; Jian-Zhi Gao; Jing-Li Du; Li-Xin Wei
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

6.  Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis.

Authors:  Xiao-Bin Gu; Tian Tian; Xiao-Jing Tian; Xiao-Jun Zhang
Journal:  Sci Rep       Date:  2015-07-24       Impact factor: 4.379

7.  Comparison between paclitaxel-coated balloon and standard uncoated balloon in the treatment of femoropopliteal long lesions in diabetics.

Authors:  Xin Du; Feng Wang; Dan-Ming Wu; Min-Hong Zhang; Xin Jia; Ji-Wei Zhang; Bai-Xi Zhuang; Yu Zhao; Ping-Fan Guo; Wei Bi; Wei-Guo Fu; Wei Guo; Shen-Ming Wang
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

8.  Prognostic significance of glypican-3 in hepatocellular carcinoma: a meta-analysis.

Authors:  Wei-Kai Xiao; Chao-Ying Qi; Dong Chen; Shao-Qiang Li; Shun-Jun Fu; Bao-Gang Peng; Li-Jian Liang
Journal:  BMC Cancer       Date:  2014-02-18       Impact factor: 4.430

9.  Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis.

Authors:  Wei-Kai Xiao; Dong Chen; Shao-Qiang Li; Shun-Jun Fu; Bao-Gang Peng; Li-Jian Liang
Journal:  BMC Cancer       Date:  2014-02-21       Impact factor: 4.430

10.  The association between osteopontin and survival in non-small-cell lung cancer patients: a meta-analysis of 13 cohorts.

Authors:  Ying Wang; Jin Yang; Hui Liu; Ji-Rui Bi; Ying Liu; Yan-Yan Chen; Ji-Yu Cao; You-Jin Lu
Journal:  Onco Targets Ther       Date:  2015-11-26       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.